IDARUBITSIN (Idarubicin).

     (7S- cis) -9 Atsetil-7--[(3-amino-2, 3,6 - tridezoksi-? L liksogeksopiranozil) Oxy] -7,8,9,10 - tetrahydro-6, 9.11 - trioksi-5, 12-naftatsendion.

     Synonym : Zavedos, Zavedos.

     The structure is close to rubomitsinu (daunorubitsinu).

     Available as hydrochloride.

     If ingestion is rapidly absorbed in the digestive tract, bioavailability of 18-39%, S-max 2-4 h, T? 10-35 h; in cells into idarubitsinol Preserving the antitumor activity appears kidneys.

     Applied with lymphoma, leukemia and acute mieloblastnom nelimfotsitarnoy leukaemia, cancer of the lungs.

     Assign inside and intravenously.

     Intravenous adults impose on the 12 mg / m 2, children under 10 mg / m 2 daily for 3 days every 3-4 weeks.

     Inside designate dose of 30 mg / m 2 (in combination with other drugs-15 mg / m 2) within 3 days every 3 weeks.

     Possible side effects : granulotsitopeniya, thrombocytopenia, anemia, nausea, vomiting, stomatitis, disruption of the liver, Alopecia, kardiotoksicheskie effects (adults, heart failure), allergic reactions, sklerozirovanie vein after intravenous injection).

     Contraindications : heart disease, mielosupressiya, disruption of the liver and (or) kidney infections, pregnancy, breast-feeding.

     Method of issuance : Capsule to 0,005; 0.01 and 0.025 g (5, 10 and 25 mg); Powder for Injection solutions in vials of 0,005 grams (5 mg).

     Storage : List A.

Materials allowed to copy only with the active hyperlink to the handbook of medicines